Journal
MOLECULAR PHARMACEUTICS
Volume 9, Issue 10, Pages 2956-2959Publisher
AMER CHEMICAL SOC
DOI: 10.1021/mp300147v
Keywords
water-soluble manganese porphyrin; superoxide dismutase mimic; manganese superoxide dismutase deficient mice; dilated cardiomyopathy; antioxidative therapy
Funding
- Japan Society for the Promotion of Science [22300166]
- Grants-in-Aid for Scientific Research [22300166, 24650281] Funding Source: KAKEN
Ask authors/readers for more resources
Mice lacking manganese-superoxide dismutase (Mn-SOD) activity exhibit typical pathology of dilated cardiomyopathy (DCM). In the present study, the structure activity relationship between the water-soluble manganese (Mn) porphyrin with SOD activity and the in vivo pharmaceutical effect on DCM is reported. The Mn-SOD-deficient mice were treated with Mn-porphyrins for 3 weeks. The treatment of a Mn-porphyrin, MnM2Py(2)P, suppressed the progression of cardiac dilation. These results suggest that the Mn-porphyrin MnM2Py2P treatment is proposed as a potential therapy for DCM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
